These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24445826)

  • 21. Antivirals and influenza: frequency of resistance.
    Monto AS
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S110-2. PubMed ID: 18820569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.
    Lina B; Boucher C; Osterhaus A; Monto AS; Schutten M; Whitley RJ; Nguyen-Van-Tam JS
    Influenza Other Respir Viruses; 2018 Mar; 12(2):267-278. PubMed ID: 29265727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment and prophylaxis of influenza and the problem of resistance to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Postepy Hig Med Dosw (Online); 2015 Sep; 69():1087-95. PubMed ID: 26400894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter.
    Blanchon T; Mentré F; Charlois-Ou C; Dornic Q; Mosnier A; Bouscambert M; Carrat F; Duval X; Enouf V; Leport C;
    Clin Microbiol Infect; 2013 Feb; 19(2):196-203. PubMed ID: 22264308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
    Ferraris O; Escuret V; Bouscambert-Duchamp M; Lina B; Morfin F
    Pathol Biol (Paris); 2010 Apr; 58(2):e69-78. PubMed ID: 20303677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia.
    Hurt AC; Barr IG; Durrant CJ; Shaw RP; Sjogren HM; Hampson AW
    Commun Dis Intell Q Rep; 2003; 27(4):542-7. PubMed ID: 15508516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to neuraminidase inhibitors.
    Dolin R
    Clin Infect Dis; 2011 Feb; 52(4):438-9. PubMed ID: 21248366
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the effectiveness of Zanamivir and Oseltamivir against influenza A/H1N1, A/H3N2, and B.
    Kawai N; Ikematsu H; Iwaki N; Maeda T; Kawashima T; Hirotsu N; Kashiwagi S
    Clin Infect Dis; 2009 Apr; 48(7):996-7. PubMed ID: 19260819
    [No Abstract]   [Full Text] [Related]  

  • 30. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
    Mungall BA; Xu X; Klimov A
    Virus Res; 2004 Jul; 103(1-2):195-7. PubMed ID: 15163509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
    Hurt AC; Barr IG; Hartel G; Hampson AW
    Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
    Hirotsu N; Saisho Y; Hasegawa T; Shishido T
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):173-182. PubMed ID: 29284320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.
    Zaraket H; Saito R; Wakim R; Tabet C; Medlej F; Reda M; Baranovich T; Suzuki Y; Dapat C; Caperig-Dapat I; Dbaibo GS; Suzuki H
    J Med Virol; 2010 Jul; 82(7):1224-8. PubMed ID: 20513088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation.
    Saito R; Sato I; Suzuki Y; Baranovich T; Matsuda R; Ishitani N; Dapat C; Dapat IC; Zaraket H; Oguma T; Suzuki H
    Pediatr Infect Dis J; 2010 Oct; 29(10):898-904. PubMed ID: 20442686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
    Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
    Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir.
    Kawai N; Ikematsu H; Iwaki N; Kawashima T; Maeda T; Mitsuoka S; Kondou K; Satoh I; Miyachi K; Yamaga S; Shigematsu T; Hirotsu N; Kashiwagi S
    J Infect; 2007 Sep; 55(3):267-72. PubMed ID: 17604839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
    Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
    Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.